Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe.

All 20 eyes completed 24-month follow-up.

In diabetic macular edema, central foveal thickness decreased by 197.7 ± 65.7 µm (39.3%; 95% CI 162.5-237.3; p < 0.001; d = 3.01), and BCVA improved by 4.55 ± 1.04 lines (~23 ETDRS letters; 95% CI 4.00-5.09; p < 0.001; d = 4.39).

All 20 eyes (100%) achieved ≥ 3 Snellen lines gain and ≥20% central foveal thickness reduction; 80% reached final BCVA ≥ 7 lines.

A linear mixed-effects model showed a significant time effect ( p < 0.001) but no time × group interaction (central foveal thickness p = 0.84; BCVA p = 0.51), indicating concordant trajectories across diseases.